Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
$12.81
+0.6%
$11.65
$4.88
$19.58
$277.98MN/A96,775 shs9,839 shs
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$5.24
-4.9%
$4.48
$2.94
$10.25
$295.15M3.05142,575 shs29,754 shs
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
$4.00
$3.39
$0.72
$6.24
$258.25M2.27932,836 shsN/A
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
$1.53
+11.7%
$0.72
$0.11
$3.91
$49.71M11.0820.92 million shs57.37 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
-2.38%-5.84%+8.99%+81.34%+1,272,999,900.00%
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
+12.68%+11.31%+20.04%+70.59%+12.91%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.00%0.00%+0.50%+354.18%-13.04%
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
+2.24%+15.13%-24.73%+727.29%+136,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
1.3047 of 5 stars
3.60.00.00.00.01.70.6
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
3.4253 of 5 stars
4.24.00.00.01.92.50.0
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
3.00
Buy$33.00157.61% Upside
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
3.13
Buy$12.13131.39% Upside
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
2.44
Hold$11.75193.75% Upside
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest KLTO, FHTX, INZY, and AARD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$40.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$4.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$15.00 ➝ $4.00
5/15/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.00
5/15/2025
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.00
5/14/2025
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/14/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
4/30/2025
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/AN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$23.50M12.43N/AN/A($0.82) per share-6.39
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/A$0.90 per shareN/A
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/A$0.04 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
-$20.59MN/A0.00N/AN/AN/AN/AN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-$86.62M-$1.36N/AN/AN/A-342.23%N/A-27.28%8/6/2025 (Estimated)
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
-$6.15M-$0.36N/AN/AN/A-1,779.01%-275.01%N/A

Latest KLTO, FHTX, INZY, and AARD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.36N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A-$0.08N/A-$0.08N/AN/A
5/14/2025N/A
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
-$0.70-$0.71-$0.01-$0.71N/AN/A
5/14/2025Q1 2025
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million
5/14/2025Q1 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.43-$0.44-$0.01-$0.44N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
N/AN/AN/AN/AN/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/AN/A
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
25.86
25.86
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
N/A
3.16
3.16
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.65
2.19
2.19
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A
0.29
0.29

Institutional Ownership

CompanyInstitutional Ownership
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
61.55%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
88.30%
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
20.07%

Insider Ownership

CompanyInsider Ownership
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
7.58%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
12.18%
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
26.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
1821.70 millionN/AN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
12055.74 million51.52 millionOptionable
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
5064.56 million56.70 millionOptionable
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A32.49 million23.82 millionN/A

Recent News About These Companies

KLTO - Klotho Neurosciences Inc Chart - Morningstar
Best Penny Stocks To Research - June 10th
Boosting Klotho Protein Slows Aging and Enhances Health
Klotho Neurosciences faces Nasdaq delisting risk

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aardvark Therapeutics stock logo

Aardvark Therapeutics NASDAQ:AARD

$12.81 +0.08 (+0.63%)
As of 01:23 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Foghorn Therapeutics stock logo

Foghorn Therapeutics NASDAQ:FHTX

$5.24 -0.27 (-4.90%)
As of 02:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Inozyme Pharma stock logo

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)
As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Klotho Neurosciences stock logo

Klotho Neurosciences NASDAQ:KLTO

$1.53 +0.16 (+11.66%)
As of 01:53 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.